CBD of Denver Inc. Announces Annual Disclosure and Filing of Financial Statements
Denver, Colorado--(Newsfile Corp. - May 2, 2024) - CBD of Denver, Inc. (OTC Pink: CBDD) has filed its financial results...
News
CirrusMD’s Physician-first Virtual Care Now Accessible Via Partnership With Blackwell Captive Solutions, Changing Healthcare Delivery in the U.S.
ful. Health Partners With Blackwell Captive Solutions to Deliver Innovative Cost-Containment Solutions, Featuring CirrusMD's Physician-Led Care, Ensuring Payers Benefit From...
Invitation to Live Presentation of Senzime’s First Quarter 2024 Report
UPPSALA, SWEDEN / ACCESSWIRE / May 2, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime invites investors, analysts, and media to a webcast...
Quest Supports Expansion of Community Center and Provides No-Cost Wellness Testing to Newark Faith Community
NORTHAMPTON, MA / ACCESSWIRE / May 2, 2024 / Quest Diagnostics: At a glance:Quest worked with St. James Health in...
Tocca Life Holdings Inc. Announces Exciting Developments in the World of Indoor Rock Climbing
WINTER PARK, FL / ACCESSWIRE / May 2, 2024 / Tocca Life Holdings, Inc. (OTC PINK:TLIF) is thrilled to share...
Theralase(R) Expands Clinical Team
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Bausch Health Announces First Quarter 2024 Results
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in...
Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform
Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR,...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for...
Planet 13 Announces Release Date of First Quarter 2024 Financial Results
LAS VEGAS, NV / ACCESSWIRE / May 2, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH) ("Planet 13" or the "Company"),...
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab...
Cerevance Achieves First Milestone in Research Collaboration with Merck
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel...
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a...
QHSLab, Inc. Enhances Leadership Team with Dr. Marcos Sanchez-Gonzalez as New VP of Medical and Scientific Affairs
WEST PALM BEACH, FL, May 02, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a leader in digital...
Veru to Present at the GLP-1 Based Therapeutics Summit
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on...
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted...
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today...
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces...